»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ;ZUj2WxE
b]b>i]n
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 *Z"`g
%,;
avq$aq(3&
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© DAb/B
1.Antigen presenting cell£¨APC£© I+H~ 5zq.
2.Activation induced cell death£¨AICD£© g_cED15
3.Chemokine }qso}
WI
4.Major histocompatibility complex£¨MHC£© W"Y)a|rG%
5.immunotolerance
j5/pVXO
ZwBz\jmbP
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© ~BuzI9~7P
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ j7Fb4;o{
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà j%s,%#al
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ O8.xt|
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ Y
M:9m)
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã nDdY~f.B
iSO xQ
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© 7he,(V
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ FTCIfW
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ AuQ|CXG-\
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ Qw2`@P8W
Hi={(Z5tC4
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ tV(iC~/
C/Q20
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 pRV.\*:c
8%CznAO"?W
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ aInt[D(
1.Antigenic determinant 39 }e
}W"
2.IgSF [T r7SU#x
3.MBL;¾¶ 8_!qoW@B
4.chemokine ]Ik~TW&
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ `3\U9ZH23
6.TCR-CD3¸´ºÏÎï N9 M}H#
7.FADD£¨Fas-associated protein with death domain£© *,G<X^
8.AIDS 'S6zk wC]
9.Tumor rejection antigen 5V/&4$.U!
10.AICD gS<p~LP
f
>97YK =
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ MX
aik+2
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© \m|5Aqs
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ D Z*c.|W
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ 1R@G7m
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì 1oO(;--u_
c\ZI
5&4jT
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ ^Ak?2,xB#+
uB"B{:Kz
9<rs3 84
רҵ¿Î ÃâÒßѧ T4:H:
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê HR?T
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell c=tbl|Cq
5. Fc¦Å receptor 6. Cytokine
spP[S"gI
¶þ¡¢ ÎÊ´ðÌâ :7X4VHw/
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 3L==p`
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ 8OOAPp$%|
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ C1f$^N
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 rEp\ld
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠO\Y*s
bJPKe]spJ=
0B1nk!F
J1(SL~e],
8cZ[Kl%
"a;$uW
@.6
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 'J*'{
3>3t(M|
~1TT ?H
רҵ¿Î ÃâÒßѧ }#.OJub
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê p/0dtnXa(
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen T] H'l
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin n'vdA !R
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test < (9
BO &
9. Hybridoma technic 10.Mitogen vt"bB
11.Dentritic cell 12.Immunoproliferation r-S%gG}~E
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ E
dc3YSg%;
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ tol-PJS}
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ`;G@qp:A
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ <}&J|()
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ ~
~WY?I-
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ kn$SG
'Kmf6iK>[
(oCpQDab@
pIrL7Pb0
7a_u=\,
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ $p
Pc}M[h
d+h~4'ebv
evE:FiDm(j
רҵ¿Î ÃâÒßѧ ae3 Gn}tf
Ò»¡¢ Ãû´Ê½âÊÍ w"kBAi&
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï It'kO jx]
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà :Eg4^,QX
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ Ug#B
( }/
¶þ¡¢ ÎÊ´ðÌâ 'T|QG@q
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ /&=y_%VR
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ hE\gXb
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ Cvt/ot-J?
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ `}
'o2oZnG
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ "_rpErm
}
T.{]t6t$U
s}gdi
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ oO
&%&;[/A
=td(}3|D
Y
!_>/ r
רҵ¿Î ÃâÒßѧ PEtr8J$uB
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê Ba%b]vp
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR SrWmV@"y
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA 1TN+pmc}@
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM oB!-JX9
¶þ¡¢ ÎÊ´ðÌâ l@<Jp *|
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ #zn`)n
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£
6l|S
Gt\
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ 8fWIZ
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ cn_KHz=
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ {4R;C~E8
V8%( h[
FePWr7Ze
1[Jv9S*f/
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]4_)WUS.c
8;,(D#p
}Mc&yjhMrg
רҵ¿Î ÃâÒßѧ y2x)<.cDP
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 0ARj3
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule 9aKCO4
5. Autogous mixed lymphoyte reaction d6e]aO=g
¶þ¡¢ ÎÊ´ðÌâ {*qz<U>
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ +oa>k
0
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ 6~8X/
-02
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠB}h8c
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ 8&y3oxA,
3)~z~p7
9D& 22hL4
Si[xyG6=
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ F!6;<!&